Homology modeling of the human 5-HT1A, 5-HT2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation

Abstract5-HT1A serotonin and D1 dopamine receptor agonists have been postulated to be able to improve negative and cognitive impairment symptoms of schizophrenia, while partial agonists and antagonists of the D2 and 5-HT2A receptors have been reported to be effective in reducing positive symptoms. There is therefore a need for well-defined homology models for the design of more selective antipsychotic agents, since no three-dimensional (3D) crystal structures of these receptors are currently available. In this study, homology models were built based on the high-resolution crystal structure of the β2-adrenergic receptor (2RH1) and further refined via molecular dynamics simulations in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayer system with the GROMOS96 53A6 united atom force field. Docking evaluations with representative agonists and antagonists using AutoDock 4.2 revealed binding modes in agreement with experimentally determined site-directed mutagenesis data and significant correlations between the computed and experimental pKi values. The models are also able to distinguish between antipsychotic agents with different selectivities and binding affinities for the four receptors, as well as to differentiate active compounds from decoys. Hence, these human 5-HT1A, 5-HT2A, D1 and D2 receptor homology models are capable of predicting the activities of novel ligands, and can be used as 3D templates for antipsychotic drug design and discovery.

[1]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[2]  J. Javitch,et al.  Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. , 1996, Molecular pharmacology.

[3]  A. Sali,et al.  Modeller: generation and refinement of homology-based protein structure models. , 2003, Methods in enzymology.

[4]  H. Akil,et al.  Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.

[5]  B. Kobilka,et al.  Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. , 1992, Molecular pharmacology.

[6]  B. Roth,et al.  A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  Zhi-Yuan Su,et al.  Predictions of Binding for Dopamine D2 Receptor Antagonists by the SIE Method , 2009, J. Chem. Inf. Model..

[8]  D. Eisenberg,et al.  VERIFY3D: assessment of protein models with three-dimensional profiles. , 1997, Methods in enzymology.

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  Sudip Roy,et al.  Headgroup mediated water insertion into the DPPC bilayer: a molecular dynamics study. , 2011, The journal of physical chemistry. B.

[11]  T. Gallaher,et al.  Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.

[12]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[13]  M. Millan,et al.  Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors , 1996, Neuropharmacology.

[14]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[15]  Christian Kandt,et al.  Setting up and running molecular dynamics simulations of membrane proteins. , 2007, Methods.

[16]  H. Weinstein,et al.  Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. , 2003, Molecular Pharmacology.

[17]  B. Kobilka,et al.  Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.

[18]  Ferran Sanz,et al.  Multi‐Receptor Binding Profile of Clozapine and Olanzapine: A Structural Study Based on the New β2 Adrenergic Receptor Template , 2008, ChemMedChem.

[19]  William J. Allen,et al.  GridMAT‐MD: A grid‐based membrane analysis tool for use with molecular dynamics , 2009, J. Comput. Chem..

[20]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[21]  Alan E Mark,et al.  On the Validation of Molecular Dynamics Simulations of Saturated and cis-Monounsaturated Phosphatidylcholine Lipid Bilayers: A Comparison with Experiment. , 2010, Journal of chemical theory and computation.

[22]  L. Naylor,et al.  Investigation of the Role of Conserved Serine Residues in the Long Form of the Rat D2 Dopamine Receptor Using Site‐Directed Mutagenesis , 1996, Journal of neurochemistry.

[23]  P. Seeman,et al.  Dopamine D1 receptor mutagenesis: role of amino acids in agonist and antagonist binding. , 1993, Biochemical and biophysical research communications.

[24]  B. Ellenbroek.  Psychopharmacological treatment of schizophrenia: What do we have, and what could we get? , 2012, Neuropharmacology.

[25]  K. Neve,et al.  Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.

[26]  W. Im,et al.  Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.

[27]  Michael R. Braden,et al.  Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor , 2007, Molecular Pharmacology.

[28]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[29]  J Hermans,et al.  Hydrophilicity of cavities in proteins , 1996, Proteins.

[30]  Alexander D. MacKerell,et al.  Comparison of protein force fields for molecular dynamics simulations. , 2008, Methods in molecular biology.

[31]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[32]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[33]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[34]  Leszek Rychlewski,et al.  Fold-recognition detects an error in the Protein Data Bank , 2002, Bioinform..

[35]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[36]  R. Sowdhamini,et al.  Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. , 2009, Molecular bioSystems.

[37]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[38]  H. Hartman,et al.  Iloperidone binding to human and rat dopamine and 5-HT receptors. , 1996, European journal of pharmacology.

[39]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[40]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[41]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[42]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[43]  Thomas M Frimurer,et al.  Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.

[44]  H Weinstein,et al.  Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor , 1996, The Journal of Biological Chemistry.

[45]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[46]  Stefan Paula,et al.  Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/endoplasmic reticulum calcium ATPase. , 2010, Biophysical chemistry.

[47]  A. Newman-Tancredi,et al.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties , 2011, Psychopharmacology.

[48]  Andreas Kukol,et al.  Lipid Models for United-Atom Molecular Dynamics Simulations of Proteins. , 2009, Journal of chemical theory and computation.

[49]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[50]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[51]  N. Pollock,et al.  Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. , 1992, The Journal of biological chemistry.

[52]  H. Lester,et al.  The role of conserved aspartate and serine residues in ligand binding and in function of the 5‐HT1A receptor: A site‐directed mutation study , 1992, FEBS letters.

[53]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[54]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[55]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[56]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[57]  Durba Sengupta,et al.  Molecular modeling of the human serotonin(1A) receptor: role of membrane cholesterol in ligand binding of the receptor. , 2011, Molecular bioSystems.

[58]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[59]  Ian T. Crosby,et al.  Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[60]  B. Roth,et al.  Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. , 2009, Bioorganic & medicinal chemistry.

[61]  H. Kikkawa,et al.  Differential contribution of two serine residues of wild type and constitutively active β2‐adrenoceptors to the interaction with β2‐selective agonists , 1997, British journal of pharmacology.

[62]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[63]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[64]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Poso,et al.  Studying the catechol binding cavity in comparative models of human dopamine D2 receptor. , 2011, Journal of molecular graphics & modelling.

[66]  T. Lundstedt,et al.  Classification of G‐protein coupled receptors by alignment‐independent extraction of principal chemical properties of primary amino acid sequences , 2002, Protein science : a publication of the Protein Society.

[67]  Christian Kandt,et al.  Membrane protein simulations with a united-atom lipid and all-atom protein model: lipid–protein interactions, side chain transfer free energies and model proteins , 2006, Journal of physics. Condensed matter : an Institute of Physics journal.

[68]  U. B. Pedersen,et al.  Functional Importance of the Carboxyl Tail Cysteine Residues in the Human D1 Dopamine Receptor , 1995, Journal of neurochemistry.

[69]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997 .

[70]  O. Berger,et al.  Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.

[71]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[72]  P. Chanda,et al.  Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. , 1993, Molecular pharmacology.

[73]  H. Akil,et al.  Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.

[74]  Qi Wang,et al.  Subtype Selectivity of Dopamine Receptor Ligands: Insights from Structure and Ligand-Based Methods , 2010, J. Chem. Inf. Model..

[75]  Hao Fan,et al.  Refinement of homology‐based protein structures by molecular dynamics simulation techniques , 2004, Protein science : a publication of the Protein Society.

[76]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[77]  J. Venter,et al.  Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. , 1988, The Journal of biological chemistry.

[78]  B. Roth,et al.  A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.

[79]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[80]  Andreas Bender,et al.  Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..

[81]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[82]  Pang-Ning Tan,et al.  Receiver Operating Characteristic , 2009, Encyclopedia of Database Systems.

[83]  H. Kikkawa,et al.  The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.

[84]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[85]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[86]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[87]  H. Hartman,et al.  Effects of atypical antipsychotic agents on social behavior in rodents , 1993, Pharmacology Biochemistry and Behavior.

[88]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[89]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.